Taysha Gene Therapies Files 8-K for Reg FD Disclosure

TL;DR

**Taysha just dropped an 8-K for Reg FD, likely signaling important news is coming or just happened.**

AI Summary

Taysha Gene Therapies, Inc. filed an 8-K on January 10, 2024, to report a Regulation FD Disclosure and Financial Statements and Exhibits. This filing indicates that the company is providing information to the public, likely related to a recent event or announcement, to ensure fair and broad dissemination of material non-public information. For investors, this matters because it signals that Taysha is adhering to transparency requirements, potentially in anticipation of or following a significant corporate development that could impact its stock, TSHA.

Why It Matters

This filing ensures Taysha Gene Therapies is transparent with investors, providing timely access to information that could influence stock performance and investor decisions.

Risk Assessment

Risk Level: low — This 8-K is a routine disclosure filing and does not inherently present new risks, but rather indicates compliance with regulatory transparency.

Analyst Insight

A smart investor would monitor Taysha Gene Therapies' news channels and subsequent filings for the specific information disclosed under Regulation FD, as this filing itself is a procedural announcement of a disclosure.

Key Players & Entities

• Taysha Gene Therapies, Inc. (company) — the registrant filing the 8-K
• January 10, 2024 (date) — date of earliest event reported and filing date
• TSHA (company) — trading symbol for Taysha Gene Therapies, Inc. Common Stock
• The Nasdaq Stock Market LLC (company) — exchange where Taysha's Common Stock is registered

FAQ

Key Financial Figures

• $0.00001 — nge on which registered Common Stock, $0.00001 par value TSHA The Nasdaq Stock Mar

Filing Documents

• d674544d8k.htm (8-K) — 25KB
• d674544dex991.htm (EX-99.1) — 13KB
• 0001193125-24-005637.txt ( ) — 166KB
• tsha-20240110.xsd (EX-101.SCH) — 3KB
• tsha-20240110_lab.xml (EX-101.LAB) — 18KB
• tsha-20240110_pre.xml (EX-101.PRE) — 11KB
• d674544d8k_htm.xml (XML) — 3KB

01

Item 7.01 Regulation FD Disclosure. On January 10, 2024, Taysha Gene Therapies, Inc. issued a press release entitled "Taysha Gene Therapies Announces First Pediatric Patient Dosed with TSHA-102 in REVEAL Phase 1/2 Pediatric Trial in Rett Syndrome." A copy of the press release is furnished as Exhibit 99.1 to this Current Report on Form 8-K. The information in this Item 7.01 of this Current Report on Form 8-K (including Exhibit 99.1) is being furnished and shall not be deemed "filed" for purposes of Section 18 of the Securities Exchange Act of 1934, as amended (the " Exchange Act "), or otherwise subject to the liabilities of that Section, nor shall it be deemed incorporated by reference in any filing under the Securities Act of 1933, as amended, or the Exchange Act, except as expressly set forth by specific reference in such a filing.

Financial Statements and Exhibits

Financial Statements and Exhibits. (d) Exhibits Exhibit No. Description 99.1 Press Release, dated January 10, 2024. 104 Cover Page Interactive Data File (the cover page XBRL tags are embedded within the inline XBRL document)

SIGNATURES

SIGNATURES Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized. Taysha Gene Therapies, Inc. By: /s/ Kamran Alam Date: January 10, 2024 Kamran Alam Chief Financial Officer

View Full Filing

View this 8-K filing on SEC EDGAR